COMMUNIQUÉS West-GlobeNewswire

-
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
03/06/2024 -
L’anticorps MCLA-129 produit par Merus ou la promesse d’une monothérapie efficace dans le traitement du CPNPC présentant une mutation de l’exon 14 du gène MET - une présentation sous forme de poster est prévue lors du congrès annuel 2024 de l’ASCO®
03/06/2024 -
NADP Push for Greater Access to Dental Benefits Gaining Traction in Congress
03/06/2024 -
Conor McGregor and Virat Kohli Collaborate to Launch TIDL's Innovative Pain Relief Products in India
03/06/2024 -
Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility
03/06/2024 -
7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic
03/06/2024 -
Oswego Health Partners with Wellthy to Deliver Comprehensive Caregiving Support to Employees and their Families
03/06/2024 -
Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
03/06/2024 -
ALK launches new growth strategy and 2028 financial ambitions
03/06/2024 -
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
03/06/2024 -
HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage
03/06/2024 -
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
03/06/2024 -
CenTrak Announces Partnership with The Leapfrog Group
03/06/2024 -
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
03/06/2024 -
Valneva annonce la publication de deux essais de Phase 2 sur la maladie de Lyme dans le Lancet Infectious Diseases
03/06/2024 -
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
03/06/2024 -
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
03/06/2024 -
Nika Pharmaceuticals, Inc. (NIKA) Presents Its Business Strategy
03/06/2024 -
Novo Nordisk A/S - share repurchase programme
03/06/2024
Pages